Tri-norinyl 28

  • Contraception

Tri-norinyl 28 Generic Name & Formulations

General Description

Norethindrone 0.5mg, ethinyl estradiol 35micrograms (7 tabs); norethindrone 1mg, ethinyl estradiol 35micrograms (9 tabs); norethindrone 0.5mg, ethinyl estradiol 35micrograms (5 tabs); inert (7 tabs).

Pharmacological Class

Progestin + estrogen.

How Supplied

Packs—3, 6


Tri-norinyl 28 Indications


Oral contraception.

Tri-norinyl 28 Dosage and Administration


1 tab daily for 28 days; repeat.


Not applicable.

Tri-norinyl 28 Contraindications


Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X). Concomitant ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Tri-norinyl 28 Boxed Warnings

Boxed Warning

Cigarette smoking increases risk of serious cardiovascular events.

Tri-norinyl 28 Warnings/Precautions


Increased risk of cardiovascular events (eg, stroke, MI) esp. in cigarette smokers >35yrs of age; not recommended. Discontinue if thrombotic event, unexplained visual changes, jaundice, migraine or other severe headaches occur, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Uncontrolled hypertension. Gallbladder disease. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Hypertriglyceridemia. Depression. Fluid rentention. Monitor blood pressure. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.

Tri-norinyl 28 Pharmacokinetics

See Literature

Tri-norinyl 28 Interactions


See Contraindications. ALT elevations with HCV regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; discontinue Tri-Norinyl prior to starting HCV regimen and restart 2wks after completion. Antagonized by rifampin, phenobarbital, phenytoin, carbamazepine, St. John's wort. Efficacy may be reduced by ampicillin, tetracycline, griseofulvin, phenylbutazone. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins).

Tri-norinyl 28 Adverse Reactions

Adverse Reactions

Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, headache, intolerance to contact lenses; serious thromboembolic events, liver disease.

Tri-norinyl 28 Clinical Trials

See Literature

Tri-norinyl 28 Note

Not Applicable

Tri-norinyl 28 Patient Counseling

See Literature